353 related articles for article (PubMed ID: 28202741)
1. Seasonal Influence on the Risk of Relapse at a Rise of Antineutrophil Cytoplasmic Antibodies in Vasculitis Patients with Renal Involvement.
Kemna MJ; Cohen Tervaert JW; Broen K; Timmermans SAMEG; van Paassen P; Damoiseaux JGMC
J Rheumatol; 2017 Apr; 44(4):473-481. PubMed ID: 28202741
[TBL] [Abstract][Full Text] [Related]
2. Increase of Antimyeloperoxidase Antineutrophil Cytoplasmic Antibody (ANCA) in Patients with Renal ANCA-associated Vasculitis: Association with Risk to Relapse.
Yamaguchi M; Ando M; Kato S; Katsuno T; Kato N; Kosugi T; Sato W; Tsuboi N; Yasuda Y; Mizuno M; Ito Y; Matsuo S; Maruyama S
J Rheumatol; 2015 Oct; 42(10):1853-60. PubMed ID: 26373560
[TBL] [Abstract][Full Text] [Related]
3. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
[TBL] [Abstract][Full Text] [Related]
4. Association Between Reappearance of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies.
Watanabe H; Sada KE; Matsumoto Y; Harigai M; Amano K; Dobashi H; Fujimoto S; Usui J; Yamagata K; Atsumi T; Banno S; Sugihara T; Arimura Y; Matsuo S; Makino H;
Arthritis Rheumatol; 2018 Oct; 70(10):1626-1633. PubMed ID: 29790303
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
7. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
8. Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement.
Córdova-Sánchez BM; Mejía-Vilet JM; Morales-Buenrostro LE; Loyola-Rodríguez G; Uribe-Uribe NO; Correa-Rotter R
Clin Rheumatol; 2016 Jul; 35(7):1805-16. PubMed ID: 26852317
[TBL] [Abstract][Full Text] [Related]
9. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
[TBL] [Abstract][Full Text] [Related]
10. The avidity of PR3-ANCA in patients with granulomatosis with polyangiitis during follow-up.
Kemna MJ; Schlumberger W; van Paassen P; Dähnrich C; Damoiseaux JG; Cohen Tervaert JW
Clin Exp Immunol; 2016 Aug; 185(2):141-7. PubMed ID: 27009928
[TBL] [Abstract][Full Text] [Related]
11. Is serum HMGB1 a biomarker in ANCA-associated vasculitis?
de Souza A; Westra J; Bijzet J; Limburg PC; Stegeman CA; Bijl M; Kallenberg CG
Arthritis Res Ther; 2013; 15(5):R104. PubMed ID: 24007972
[TBL] [Abstract][Full Text] [Related]
12. Relevance of ANCA positivity at the time of renal transplantation in ANCA associated vasculitis.
Geetha D; Lee SM; Shah S; Rahman HM
J Nephrol; 2017 Feb; 30(1):147-153. PubMed ID: 26646552
[TBL] [Abstract][Full Text] [Related]
13. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
Pullerits R; Ljevak M; Vikgren J; Bokarewa M
Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
[TBL] [Abstract][Full Text] [Related]
14. Determinants of renal and patient outcomes in a Spanish cohort of patients with ANCA-associated vasculitis and renal involvement.
Marco H; Draibe J; Villacorta J; Quintana LF; Martin N; Garcia-Osuna R; Cabre C; Martín-Gómez MA; Balius A; Saurina A; Picazo M; Gich-Saladich I; Navarro-Díaz M; Praga M; Cavero T; Ballarin J; Díaz-Encarnación MM;
Clin Rheumatol; 2018 Apr; 37(4):1065-1074. PubMed ID: 29520673
[TBL] [Abstract][Full Text] [Related]
15. The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study.
McDermott G; Fu X; Cook C; Ahola C; Doliner B; Hanberg J; Stone JH; Choi HK; Zhang Y; Wallace ZS
Ann Rheum Dis; 2022 Oct; 81(10):1438-1444. PubMed ID: 35697489
[TBL] [Abstract][Full Text] [Related]
16. Two types of myeloperoxidase-antineutrophil cytoplasmic autoantibodies with a high affinity and a low affinity in small vessel vasculitis.
Yoshida M; Sasaki M; Nakabayashi I; Akashi M; Tomiyasu T; Yoshikawa N; Kojima T; Ohno N; Yamada M
Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S28-32. PubMed ID: 19646343
[TBL] [Abstract][Full Text] [Related]
17. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.
Morgan MD; Szeto M; Walsh M; Jayne D; Westman K; Rasmussen N; Hiemstra TF; Flossmann O; Berden A; Höglund P; Harper L;
Arthritis Res Ther; 2017 Jun; 19(1):129. PubMed ID: 28592297
[TBL] [Abstract][Full Text] [Related]
18. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data.
de Joode AAE; Sanders JSF; Puéchal X; Guillevin LP; Hiemstra TF; Flossmann O; Rasmussen N; Westman K; Jayne DR; Stegeman CA
Rheumatology (Oxford); 2017 Nov; 56(11):1894-1901. PubMed ID: 28977502
[TBL] [Abstract][Full Text] [Related]
19. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
20. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Karras A; Pagnoux C; Haubitz M; Groot K; Puechal X; Tervaert JWC; Segelmark M; Guillevin L; Jayne D;
Ann Rheum Dis; 2017 Oct; 76(10):1662-1668. PubMed ID: 28546260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
